Evaluation of 3–5 months’ add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real-world, observational study

By Schlick Werner   Pohl Wolfgang   Pfeiffer Karl P.   Aigner Kurt   Forche Günter   Kneussl Meinhard   Zwick Hartmut  

Current Medical Research and Opinion, Vol. 26, Iss. 3, 2010-03 ,pp. : 561-570

Informa Healthcare

Access to resources Recommend Favorite

Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting β2-agonists: addition of montelukast in an open-label pilot study

By Dupont Lieven   Potvin Emmanuel   Korn Dana   Lachman Albert   Dramaix Michèle   Gusman Julie   Peché Rudi  

Current Medical Research and Opinion, Vol. 21, Iss. 6, 2005-06 ,pp. : 863-870

Informa Healthcare

Access to resources Recommend Favorite

Safety and efficacy of mirabegron as ‘add‐on’ therapy in patients with overactive bladder treated with solifenacin: a post‐marketing, open‐label study in Japan (MILAI study)

By  

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 612-622

John Wiley & Sons Inc

Access to resources Recommend Favorite

Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study

By Borderias Luis   Mincewicz Grzegorz   Paggiaro Pier Luigi   Guilera Magda   Sazonov Kocevar Vasilisa   Taylor Stephanie D.   Badia Xavier  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 721-730

Informa Healthcare

Access to resources Recommend Favorite

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

By Choi Seong Hye   Park Kyung Won   Na Duk L.   Han Hyun Jeong   Kim Eun-Joo   Shim Yong S.   Lee Jae-Hong    

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1375-1383

Informa Healthcare

Access to resources Recommend Favorite